Chemotherapy in elderly patients with advanced lung cancer part II: Treatment of Non-Small Cell Lung Cancer (NSCLC)

Onkologie

Volumn 27, Issue 6, 2004, Pages 583-588

  Honeckera, F ^a   Weddingb, U ^b   Bokemeyer, C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Chemotherapy; Elderly patients; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE;

AGE DISTRIBUTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG POTENCY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; OUTCOMES RESEARCH; QUALITY OF LIFE; REVIEW; SEX ROLE; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DRUG THERAPY; GERIATRICS; HUMANS; INCIDENCE; LUNG NEOPLASMS; PALLIATIVE CARE; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 10844237128     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081344     Document Type: Review

References (38)

1. Edwards BK, Howe HL, Ries LAG, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG: Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on the U.S. cancer burden. Cancer 2002;94:2766-2792.
2. Honecker F, Wedding U, Bokemeyer C: Chemotherapy in elderly patients with advanced lung cancer. Part I: General aspects and treatment of small cell lung cancer (SCLC). Onkologie 2004;27:500-505.
3. Weinmann M, Jeremic B, Toomes H, Friedel G, Bamberg M: Treatment of lung cancer in the elderly. Part I: Non-small cell lung cancer. Lung Cancer 2003;39:233-253.
4. Naruke T, Goya T, Tsuchiya R, Suemasu K: Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96:440-447.
5. O'Rourke MA, Feussner J, Feigl P, Laszlo J: Age trends of lung cancer stage at diagnosis. Implications for lung cancer screening in the elderly. JAMA 1987;258:921-926.
6. Non-Small Cell Lung Cancer Collaborative Group (NSCLCCG): Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
7. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr., Green MR: Improved survival in stage III nonsmall cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial. J Natl Cancer Inst 1996;88:1210-1215.
8. Sequist LV, Lynch TJ: Aggressive treatment for the fit elderly with non-small cell lung cancer? Yes! Editorial, J Clin Oncol 2003;17:3186-3188.
9. Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, Johnson DH: Cisplatin-based therapy for elderly patients with advanced nonsmall lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181.
10. Rocha Lima CM, Herndon JE 2nd, Kosty M, Clamon G, Green MR: Therapy choices among older patients with lung carcinoma: An evaluation of two trials of the cancer and leukaemia group B. Cancer 2002;94:181-187.
11. Schild SE, Stella PJ, Geyer SM, Bonner JA, McGinnis WL, Mailliard JA, Brindle J, Jatoi A, Jett JR: The outcome of combined-modality therapy for stage III non-small cell lung cancer in the elderly. J Clin Oncol 2003;21:3201-3206.
12. Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J, Johnson D, Lawton C, Dar AR, Wasserman T, Roach M, Lee JS, Andras EJ: Age dramatically impacts on the quality-adjusted time without symptoms or toxicity (Q-Twist) in locally advanced nonsmall cell lung cancer (LA-NSCLC) - a radiation therapy oncology group (RTOG) analysis. Proceedings of the 42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology 2000;abstr 92.
13. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De Cataldis G, Iannelli A, Bilancia D, Belli M, Massidda B, Piantedosi F, Comella G, De Lena: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced nonsmall cell lung cancer. J Clin Oncol 2000;18:2529-2536.
14. Soria JC, Brisgand D, Le Chevalier T: Do all patients with advanced non-small cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 2001;12:1667-1670.
15. Koeller JM, Kwan P, Smith R, Simon J: The impact of age, performance status (PS) and chemotherapy treatment on mortality in 1244 community-based advanced non-small cell lung cancer (NSCLC) patients. Proc Am Soc Clin Oncol 2003;22:705 (abstr 2835).
16. Di Maio M, Perrone F, Gallo C, Iaffaioli RV, Manzione L, Piantedosi FV, Cigolari S, Illiano A, Barbera S, Robbiati SF, Piazza E, Ianniello GP, Frontini L, Veltri E, Catiglione F, Rosetti F, De Maio E, Maione P, Gridelli C: Supportive care in patients with advanced non-small cell lung cancer. Br J Cancer 2003;89:1013-1021.
17. Billingham LJ, Cullen MH: The benefits of chemotherapy in patient subgroups with unresectable non-small cell lung cancer. Ann Oncol 2001:12:1671-1675.
18. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC: Effectiveness of chemotherapy for advanced lung cancer in the elderly: Instrumental variable and propensity analysis. J Clin Oncol 2001;19:1064-1070.
19. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA: The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with platin and paclitaxel. Cancer 2003;98:779-778.
20. Fossella FV, Belani CP, for the TAX 326 Study Group: Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/metastatic non-small cell lung cancer (NSCLC): Analyses in elderly patients. Proc Am Soc Clin Oncol 2003,22:629 (abstr 2528).
21. Lilenbaum RC, Herndon J, List M, Desch C, Watson D, Holland J, Weeks JC, Green MR; Cancer and Leukemia Group B: Single-agent (SA) versus combination chemotherapy (CC) in advanced nonsmall cell lung cancer (NSCLC): A CALBG randomized trial of efficacy, quality of life (QOL), and cost effectiveness. Proc Am Soc Clin Oncol 2002;21:1a (abstr 2).
22. Bunn PA Jr., Lilenbaum R: Chemotherapy for elderly patients with advanced non-small cell lung cancer. Editorial. J Natl Cancer Inst 2003;95:341-343.
23. Brown JS, Eraut D, Trask C, Davidson AG: Age and the treatment of lung cancer. Thorax 1996;51:564-568.
24. Shepherd FA, Abratt RP, Anderson H, Gatzemeier U, Anglin G, Iglesias J: Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 1997;24(2 Suppl 7):50-55.
25. Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced nonsmall cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
26. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De Cataldis G, Iannelli A, Bilancia D, Belli M, Massidda B, Piantedosi F, Comella G, De Lena: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced nonsmall cell lung cancer. J Clin Oncol 2000;18:2529-2536.
27. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Garparini G, Galetta D, Iaffaioli RV, Gebbia V: Chemotherapy for elderly patients with advanced non-small cell lung cancer: The multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
28. Feliu J, Lopez Gomez L, Madronal C, Espinosa E, Espinosa J, Garcia Giron C, Martinez B, Castro J, De la Gandara I, Gonzalez Baron M, for the Oncopaz Cooperative Group: Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Cancer 1999;88:1463-1469.
29. Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, Cannon MW, Geyer S, Wiesenfeld M, Jett JR: Weekly carboplatin and paclitaxel in elderly non-small cell lung cancer patients (>or=65 years of age). Am J Clin Oncol 2003;26:441-447.
30. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamid in patients with advanced non-small cell lung cancer previously treated with platinumcontaining chemotherapy. J Clin Oncol 2000;18:2354-2362.
31. Shepherd FA, Dancey J, Ramlau R, Mattson K, Galla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Barkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2193.
32. Gridelli C, Hainsworth J: Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC. Lung Cancer 2002;38:37-41.
33. Esteban E, Gonzalez de Sande L, Fernandez Y, Corral N, Frau J, Muniz I, Vieitez JM, Palacio I, Fernandez JL, Estrada E, Lacave AJ: Prospective randomized phase II study of docetaxel versus paclitaxel administered weekly in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 2003;14:1640-1647.
34. Gemma D, Magnolfi E, Petrella PP, Salerno M, Ciorra A, Trapuzzano C, Di Seri M, Borgomastro A, Traficante D, Longo F: Single-agent chemotherapy as second-line therapy in NSCLC in elderly patients (Pts). Ann Oncol 2003:14(Suppl 4):iv64 (abstr F8).
35. Hanna NH, Shepherd FA, Rosell R, Pereira JR, De Marinis F, Fossella F, Kayitalire L, Paul S, Einhorn LH, Bunn PA: A phase III study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc Am Soc Clin Oncol 2003;22:622 (abstr 2503).
36. Copin M, Kommareddy A, Behnken D, McLeod H, Trinkaus K, Ali A, Read W, Govindan R: Gefitinib in elderly patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003;22:758 (abstr 3048).
37. Gridelli C, Maione P, Castaldo V, Rossi A: Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 2003;89:1827-1829.
38. Balducci L, Extermann M: Management of cancer in the older person: A practical approach. Oncologist 2000;5:224-237.